van der Wall SJ, Teutsch C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Paquette M, Zint K, Franca LR, Lu S, Lip GYH, Huisman MV, GLORIA-AF Investigators. Anticoagulation prescription and outcomes in relation to renal function in patients with atrial fibrillation: results from GLORIA-AF. TH Open. 2021 Feb 6;5(1):e35-42. doi: 10.1055/s-0040-1722706
van den Dries CJ, van Doorn S, Souverein P, Pajouheshnia R, Moons KGM, Hoes AW, Gerrsing G-J, van den Ham HA. The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation. TH Open. 2020 Dec 23;4(4):e417-26. doi: 10.1055/s-0040-1721499
Van Hout B, Hawe E, Cohen AT. Impact of patient characteristics on treatment outcomes in symptomatic venous thromboembolism: results of HOKUSAI-VTE randomized trial analysis. TH Open. 2020 Sep 23;4(3):e245-54. doi: 10.1055/s-0040-1716496
Skajaa N, Horvath-Puho E, Adelborg K, Prandoni P, Rothman KJ, Sorensen HT. Venous thromboembolism in Denmark: seasonality in occurrence and mortality. TH Open. 2019 Jun 18;3(2):e171-9. doi: 10.1055/s-0039-1692399.
White MV, Silvia S, Hollis K, Wooddell M, Hogue S. Differences in anaphylaxis-related risks by school grade level: findings from the EpiPen4Schools® survey. Poster presented at the 2015 ASCIA Conference; September 2015. Adelaide, Australia. [abstract] Intern Med J. 2015 Sep 3; 45(Suppl 4):3. doi: 10.1111/imj.12869
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.